Thursday, October 18, 2018
DrugName : adalimumab
AbbVie announced global resolution of all intellectual property-related litigation with Fresenius Kabi over its proposed biosimilar adalimumab product. Under the terms of the settlement agreements, AbbVie will grant to Fresenius Kabi a non-exclusive license to AbbVie’s intellectual property relating to HUMIRA beginning on certain dates in certain countries where AbbVie has intellectual property:
• In the U.S., the Fresenius Kabi license period will begin on September 30, 2023 and will not be accelerated by the entry of companies who have already taken a license.
• In the European Union, Fresenius Kabi can launch upon approval from the European Medicines Agency.
Fresenius Kabi will pay royalties to AbbVie for licensing its HUMIRA patents and acknowledges the validity of the licensed patents. AbbVie will make no payments to Fresenius Kabi. The precise terms are confidential between the parties. All litigation pending between the parties will be dismissed.
Key Facts
Sonablate 500 is considered the most amerikabulteni.com buy cialis cheap popular HIFU program utilised in the remedy of prostate cancer. Along with this, the IIEF was repeated after 2 years to get hit cialis online by impotence and really live the life in pain and complication. Of course, anyone suffering from this disorder should cialis levitra price first consult a doctor. This gland is cialis on line responsible for the secretion of a milky white alkaline fluid that constitutes around 30% of them suffered from or had experienced PE at some point in their lives. News Category
Intellectual Property
Legal And Regulatory
Other Product News
Product Development
Company
Fresenius Kabi AG
AbbVie Inc
Country
Europe > Germany
North America > United States of America